| Outcome Measures: |
Primary: Safety variables (AE, BP, pulse, plasma glucose, laboratory variables, weight and ECG, AE will be collected from the time for randomisation until follow-up visit. Safety variables and vital signs will be measured at the pre-entry, during study days -2 to 10 and at the follow-up visit. | Secondary: Pharmacokinetic variables: (Area under the plasma concentration vs. time curve (AUC), maximum plasma concentration (Cmax), time to reach maximum plasma concentration (tmax), terminal elimination half-life (t½) and apparent oral clearance (CL/F), Blood samples for analysis of plasma concentrations of AZD1656 will be collected on study days 6 and 9. The samples for analysis of glipizide will be collected on study days -1 and 6.|Pharmacodynamic variables: 24 h plasma glucose, Insulin, Samples for 24-hour plasma glucose and insulin will be collected on study days -1, 6 and 9.
|
